Search
This phase 1 trial assessed the safety and immunogenicity of an investigational tetanus/diphtheria/acellular pertussis vaccine combined with CpG 1018 adjuvant 1500 μg (Tdap-1018 1500 μg) or 3000 μg (Tdap-1018 3000 μg) in adults and adolescents.
Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Group B streptococcus (GBS) is an important cause of early- and late-onset sepsis in the newborn. Preterm infants have markedly increased susceptibility...
Neisseria meningitidis serogroups B, C, and Y cause most meningococcal disease in industrialized countries...
The Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...
The Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...
Maternal, umbilical cord, neonatal inflammatory, hematologic markers, histologic chorioamnionitis...
Are you listening? The inaugural OMOZ Workshop - towards a better understanding of otitis media
Risk factors for the association of Scedosporium in cases of cystic fibrosis (CF) and its clinical implications are poorly understood
In vitro investigations of human innate immune responses to extracellular bacteria commonly utilise killed preparations in preference to live organisms